Background: New Zealand (NZ) has a high prevalence of multiple sclerosis (MS). Worldwide, the prevalence of MS appears to be increasing. Objectives: To review all published prevalence studies undertaken in NZ to determine whether the prevalence of MS in NZ is increasing. Methods: PubMed, Medline, Scopus, Web of Knowledge, EMBASE, AMED and CINAHL were searched to identify studies reporting the prevalence of MS in NZ. Prevalence rates from the National MS Prevalence study in 2006 were compared with earlier prevalence rates for the same regions using Poisson regression. Results: Prevalence rates reported in the earlier regional studies ranged from 23.6 to 68.5/100,000 population; in the same regions in 2006, the range was 47.6-134.2/100,000 population. Prevalence rates were significantly increased in all regions studied except for the Bay of Plenty. The increase in prevalence was seen in both sexes. The sex ratio remained constant over time. Conclusions: In studies spanning almost 40 years (1968-2006), the prevalence of MS within the same regions of NZ has significantly increased whereas the sex ratio and latitudinal gradient have remained stable.

Keywords:
Multiple sclerosis, Prevalence, New Zealand, Sex ratio, Latitude gradient
1.
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
2.
Compston A, Coles A: Multiple sclerosis. Lancet 2002;359:1221-1231.
3.
Compston A: Risk factors for multiple sclerosis: race or place? J Neurol Neurosurg Psychiatry 1990;53:821-823.
4.
Sawcer S: The major cause of multiple sclerosis is environmental: genetics has a minor role - no. Mult Scler 2011;17:1174-1175.
5.
Taylor BV: The major cause of multiple sclerosis is environmental: genetics has a minor role - yes. Mult Scler 2011;17:1171-1173.
6.
Alonso A, Hernán MA: Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-135.
7.
Benito-León J: Are the prevalence and incidence of multiple sclerosis changing? Neuroepidemiology 2011;36:148-149.
8.
Hirst C, Ingram G, Pickersgill T, Swingler R, Compston DAS, Robertson NP: Increasing prevalence and incidence of multiple sclerosis in south east Wales. J Neurol Neurosurg Psychiatry 2009;80:386-391.
9.
Koch-Henriksen N, Sørensen PS: The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-532.
10.
Barnett MH, Williams DB, Day S, Macaskill P, McLeod JG: Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci 2003;213:1-6.
11.
Hammond SR, McLeod JG, Millingen KS, Stewart-Wynne EG, English D, Holland JT, McCall MG: The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988;111:1-25.
12.
McCall MG, Brereton TL, Dawson A, Millingen K, Sutherland JM, Acheson ED: Frequency of multiple sclerosis in three Australian cities - Perth, Newcastle, and Hobart. J Neurol Neurosurg Psychiatry 1968;31:1-9.
13.
Simpson S Jr, Pittas F, Van Der Mei I, Blizzard L, Ponsonby AL, Taylor B: Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951-2009. J Neurol Neurosurg Psychiatry 2011;82:180-187.
14.
Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5:932-936.
15.
Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S, Lepore V, Grand'Maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Direnzo V, Butzkueven H: Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012;7:e48078.
16.
Wallin MT, Page WF, Kurtzke JF: Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004;55:65-71.
17.
Statistics New Zealand: Profile of New Zealander responses, ethnicity question: 2006 census. 2006. http://www.stats.govt.nz.
18.
Taylor BV, Pearson JF, Clarke G, Mason DF, Abernethy DA, Willoughby E, Sabel C: MS prevalence in New Zealand, an ethnically and latitudinally diverse country. Mult Scler 2010;16:1422-1431.
19.
Poppe AY, Wolfson C, Zhu B: Prevalence of multiple sclerosis in Canada: a systematic review. Can J Neurol Sci 2008;35:593-601.
20.
Breslow NE, Day NE: Statistical Methods in Cancer Research. Lyon, International Agency for Research on Cancer, 1987, vol 1, pp 131-135.
21.
Chancellor AM, Addidle M, Dawson K: Multiple sclerosis is more prevalent in northern New Zealand than previously reported. Intern Med J 2003;33:79-83.
22.
Cuningham JA: The prevalence of disseminated sclerosis in Christchurch. NZ Med J 1972;76:417-418.
23.
Hornabrook RW: The prevalence of multiple sclerosis in New Zealand. Acta Neurol Scand 1971;47:426-438.
24.
Skegg DC, Corwin PA, Craven RS, Malloch JA, Pollock M: Occurrence of multiple sclerosis in the north and south of New Zealand. J Neurol Neurosurg Psychiatry 1987;50:134-139.
25.
Miller DH, Hornabrook RW, Dagger J, Fong R: Ethnic and HLA patterns related to multiple sclerosis in Wellington, New Zealand. J Neurol Neurosurg Psychiatry 1986;49:43-46.
26.
Allison R, Millar J: Prevalence of disseminated sclerosis in Northern Ireland. Ulster Med J 1954;23(suppl 2):5-27.
27.
McDonald WI, Halliday AM: Diagnosis and classification of multiple sclerosis. Br Med Bull 1977;33:4-8.
28.
Poskanzer D, Schapira K, Miller H: Epidemiology of multiple sclerosis in the counties of Northumberland and Durham. Acta Neurol Scand 1966;42(suppl 19):55-56.
29.
Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, Thompson AJ, Plant GT, Miller DH: MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2011;82:176-179.
30.
Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V: Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012;78:1315-1322.
31.
Acheson ED: Multiple sclerosis in British Commonwealth countries in the Southern Hemisphere. Br J Prev Soc Med 1961;15:118-125.
32.
Disanto G, Pakpoor J, Morahan JM, Hall C, Meier UC, Giovannoni G, Ramagopalan SV: Epstein-Barr virus, latitude and multiple sclerosis. Mult Scler 2013;19:362-365.
33.
Grant WB: Latitude and multiple sclerosis prevalence: Vitamin D reduces risk of Epstein-Barr virus infection. Mult Scler 2010;16:373.
34.
Houzen H, Niino M, Kikuchi S, Fukazawa T, Nogoshi S, Matsumoto H, Tashiro K: The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003;211:49-53.
35.
Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H: Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol 2010;64:331-336.
36.
Sundström P, Nyström L, Forsgren L: Prevalence of multiple sclerosis in Västerbotten County in northern Sweden. Acta Neurol Scand 2001;103:214-218.
37.
Eadie MJ, Sutherland JM, Tyrer JH: Multiple sclerosis and poliomyelitis in Australasia. BMJ 1965;1:1471-1473.
38.
Fawcett J, Skegg DCG: Geographic distribution of MS in New Zealand: evidence from hospital admissions and deaths. Neurology 1988;38:416-418.
39.
Gallagher L, Lea R: The epidemiology of multiple sclerosis in New Zealand. New Zeal Med J 2005;118:U1296.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.